Understand the source comparison
VIP for Women: Research-Grade Compound Comparison
VIP peptide availability for biological research spans multiple purity grades and synthesis methods, each with distinct implications for study reproducibility and mechanistic clarity. The table below compares key specifications that affect research outcomes wh
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- VIP peptide availability for biological research spans multiple purity grades and synthesis methods, each with distinct implications for study reproducibility and mechanistic clarity. The table below compares key specifications that affect research outcomes when selecting VIP for women-focused protocols.
- Purity
- ≥98% by HPLC, mass spec verified
- 95–97%, potential acetate interference
- Variable, 90–99% depending on synthesis complexity
- Research-grade VIP for women requires ≥98% purity to isolate peptide effects from contaminant-driven variance in hormone-sensitive assays
- Reconstitution
- Bacteriostatic water or sterile saline, stable 28 days at 2–8°C
- Requires pH adjustment to 7.2–7.4 for some assays
- Solubility varies with sequence modification
- Lyophilised VIP offers the most consistent reconstitution across female tissue types with variable pH environments
- Receptor Selectivity
- Binds VPAC1 and VPAC2 equally
- Equal binding, acetate may affect assay interference
- Can be modified for VPAC2 selectivity in reproductive tissue studies
- Native VIP binds both receptors; custom synthesis allows VPAC2-selective analogs critical for isolating reproductive vs immune effects
- Stability in Serum
- ~2 min half-life, rapid degradation by proteases
- Same as native VIP
- Can be extended to 15–30 min with D-amino acid substitutions
- Female serum contains higher protease activity during luteal phase; stabilised analogs reduce phase-dependent variance
- Cost per mg
- $180–$320 depending on batch size
- $150–$280
- $400–$900 for custom sequences
- Higher upfront cost for stabilised or selective analogs justified in multi-phase studies where VIP degradation confounds results
- The choice between native VIP and modified analogs hinges on whether the research question targets natural physiology or requires controlled receptor selectivity. Studies examining VIP for women in autoimmune contexts typically use native VIP to preserve physiological relevance, while reproductive immunology researchers increasingly use VPAC2-selective analogs to isolate effects at the maternal-fetal interface from systemic immune modulation.